ASCO 2025 Bladder Cancer

Viewing 1-20 of 45 articles

ASCO 2025: Intravesical Disitamab Vedotin (RC48) for Patients with HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Dose-Escalation Phase I Trial

ASCO 2025: Assessing Treatment Outcomes of Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer

ASCO 2025: Prognostic Utility of ctDNA Before and After Trimodality Therapy (TMT) for Muscle Invasive Bladder Cancer

ASCO 2025: Treatment Patterns and Clinical Outcomes with Platinum-Based Chemotherapy After Enfortumab Vedotin and Pembrolizumab in Patients with Metastatic Urothelial Carcinoma

ASCO 2025: IL-15RαFc Superagonist SHR-1501 with or Without Bacille Calmette Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: A Phase 1/2 Study

ASCO 2025: Correlation of Circulating Tumor DNA Dynamics with Clinical Response in Muscle-Invasive Bladder Cancer Patients Undergoing Trimodality Therapy

ASCO 2025: EV-103 Cohort H: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer – 3-Year Efficacy Results

ASCO 2025: First Survival Outcomes and Biomarker Results of SURE-01: Neoadjuvant Sacituzumab Govitecan Monotherapy, Followed by Radical Cystectomy, in Patients with Muscle-Invasive Urothelial Bladder Cancer

ASCO 2025: Trials-in-Progress – Sasanlimab as Bladder-Sparing Maintenance Treatment After Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer (MIBC): The Phase 2, SASAN-SPARING Trial

ASCO 2025: Trials-in-Progress – Intravesical Sacituzumab Tirumotecan in Participants with Intermediate-Risk Non–muscle-Invasive Bladder Cancer: The Phase 1/2 TroFuse-027 Study

ASCO 2025: MRI Radiomics as Predictor of Clinical Outcomes to Neoadjuvant Immunotherapy in Patients with Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy

ASCO 2025: MRI Radiomics to Predict Outcome of Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy

ASCO 2025: Trials-in-Progress – PUNCH03: A Phase II Study of Disitamab Vedotin Combined with Tislelizumab and Bacillus Calmette-Guerin (BCG) in HER2-Positive High-Risk Non-Muscle-Invasive Bladder Cancer

ASCO 2025: SOGUG-NEOWIN: A Phase 2, Open-Label, Multicenter, Multinational Interventional Trial Evaluating the Efficacy and Safety of Erdafitinib Monotherapy and the Combination of Erdafitinib and Cetrelimab as Neoadjuvant Treatment in Cisplatin

ASCO 2025: AURORA: A Single Arm, Multicentre, Phase II Clinical Trial of Atezolizumab Immunotherapy for Advanced Squamous Cell Carcinoma of the Bladder and Urinary Tract

ASCO 2025: Phase 1/2 Duravelo-1 Study: Preliminary Results of Nectin-4–targeting Zelenectide Pevedotin (BT8009) plus Pembrolizumab in Previously Untreated, Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer

ASCO 2025: EV-302: Long-Term Subgroup Analysis from the Phase 3 Global Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

ASCO 2025: Impact of Histological Subtypes in Patients Receiving First-Line Treatment with Enfortumab Vedotin/pembrolizumab in Advanced Metastatic Urothelial Cancer

ASCO 2025: Trials-in-Progress – a Randomized Phase 2 Study of the Efficacy and Safety of Stereotactic Body Radiation Therapy in Patients with Metastatic Urothelial Carcinoma and Oligoprogression on Maintenance Therapy with Avelumab (VOLGA 2)

ASCO 2025: Trials-in-Progress – Neoadjuvant Stereotactic Radiotherapy and Enfortumab Vedotin: A Phase I/II Study for Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer (STAR-EV)

1
2
3